What is Recombinetics?
Recombinetics is a prominent entity in the animal gene editing sector, offering advanced solutions for biomedical research, regenerative medicine, and animal agriculture. The company is particularly recognized for its expertise in developing custom gene-edited swine models, which are crucial for enhancing preclinical research and reducing the dependency on nonhuman primates. Recombinetics' core mission is to drive biomedical innovation through high-integrity services and products, catering to clients within the healthcare and agricultural industries with the aim of improving animal health and promoting sustainability.
How much funding has Recombinetics raised?
Recombinetics has raised a total of $69.8M across 10 funding rounds:
Private Equity
$540K
Private Equity
$5.7M
Multiple Rounds
$19.3M
Debt
$7M
Private Equity
$2.1M
Series A
$34M
Debt
$350K
Debt
$766K
Private Equity (2014): $540K, investors not publicly disclosed
Private Equity (2015): $5.7M, investors not publicly disclosed
Private Equity (2016): $630K, investors not publicly disclosed
Unspecified (2016): $7.7M, investors not publicly disclosed
Private Equity (2016): $11M, investors not publicly disclosed
Debt (2017): $7M, investors not publicly disclosed
Private Equity (2017): $2.1M, investors not publicly disclosed
Series A (2018): $34M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $766K backed by PPP
What's next for Recombinetics?
The recent major strategic investment signals a pivotal growth phase for Recombinetics. This significant capital injection is expected to accelerate the company's research and development initiatives, potentially expanding its custom gene-edited animal model offerings and broadening its market reach in both biomedical research and agriculture. The company's focus on integrity-driven services positions it for continued advancement in the competitive landscape of animal biotechnology, aiming to further solidify its leadership in the field.
See full Recombinetics company page
